Key points are not available for this paper at this time.
Os desfechos em pacientes com câncer de mama metastático receptor hormonal positivo pioram após uma ou mais linhas de terapia endócrina. O trastuzumab deruxtecan demonstrou eficácia em pacientes com câncer de mama metastático com baixa expressão do receptor 2 do fator de crescimento epidérmico humano (HER2) após quimioterapia prévia.
Building similarity graph...
Analyzing shared references across papers
Loading...
Aditya Bardia
Xichun Hu
Rebecca Dent
New England Journal of Medicine
Harbin Medical University
Fudan University Shanghai Cancer Center
National Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Bardia et al. (Sab,) estudaram esta questão.
www.synapsesocial.com/papers/68e587feb6db643587524983 — DOI: https://doi.org/10.1056/nejmoa2407086
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: